ArticleMolecular diversity2025
Molecular modeling aided design, synthesis and biological evaluation of quinazoline derivatives for the treatment of human cancer.
Cai-Shi Liu, Jin-Peng Tong, Ze-Yu Fang, Xiao-Meng Guo, Ting-Ting Shi, Shou-Rong Liu, Juan Sun
Abstract read
In one paragraphArticle in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Cai-Shi LiuSchool of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, People's Republic of China.
Jin-Peng TongSchool of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, People's Republic of China.
Ze-Yu FangSchool of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, People's Republic of China.
Xiao-Meng GuoSchool of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, People's Republic of China.
Ting-Ting ShiDepartment of Pharmaceutical Preparation, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, People's Republic of China.
Shou-Rong LiuDepartment of Pharmaceutical Preparation, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, People's Republic of China. lsr85463990@126.com.
Juan SunSchool of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, People's Republic of China. sunjuan18@zust.edu.cn.
Funding
Hangzhou Joint Fund of the Zhejiang Provincial Natural Science Foundation of China LHZY24H310001National Natural Science Foundation of China 22107092Science and Technology Bureau of Hangzhou 20220919Y039Science and Technology Bureau of Hangzhou 20220919Y042
6 · The paper itselfAbstract
The quinazoline scaffold serves as a fundamental framework, demonstrating potent anti-tumor activity. Employing the pharmacophore-based scaffold hopping principle, we successfully synthesized a series of FAK/PLK1 inhibitors incorporating the quinazoline scaffold. The synthesized compounds were characterized using
Indexed as
Antineoplastic AgentsDrug DesignNeoplasmsQuinazolinesApoptosisCell Cycle ProteinsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFocal Adhesion Kinase 1HumansModels, MolecularMolecular Docking SimulationPolo-Like Kinase 1Protein Kinase InhibitorsProtein Serine-Threonine KinasesAntineoplastic AgentsCell Cycle ProteinsFocal Adhesion Kinase 1Polo-Like Kinase 1Protein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene ProteinsQuinazolinesAntitumor activityFAKMolecular dockingPLK1Quinazoline
What OpenQuestion holds
Textmetadata
Read underepoch 390